R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 58.41 CNY -2.81% Market Closed
Market Cap: 5.6B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

R&G PharmaStudies Co Ltd
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Retained Earnings
ÂĄ596.1m
CAGR 3-Years
32%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Retained Earnings
ÂĄ28.2B
CAGR 3-Years
41%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Retained Earnings
ÂĄ6.6B
CAGR 3-Years
39%
CAGR 5-Years
57%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Retained Earnings
ÂĄ19.1B
CAGR 3-Years
44%
CAGR 5-Years
59%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Retained Earnings
ÂĄ9.2B
CAGR 3-Years
23%
CAGR 5-Years
45%
CAGR 10-Years
44%
W
WuXi XDC Cayman Inc
HKEX:2268
Retained Earnings
ÂĄ562.5m
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
5.6B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
57.24 CNY
Overvaluation 2%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Retained Earnings?
Retained Earnings
596.1m CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Retained Earnings amounts to 596.1m CNY.

What is R&G PharmaStudies Co Ltd's Retained Earnings growth rate?
Retained Earnings CAGR 3Y
32%

Over the last year, the Retained Earnings growth was 33%. The average annual Retained Earnings growth rates for R&G PharmaStudies Co Ltd have been 32% over the past three years .

Back to Top